CLINICAL TRIALS PROFILE FOR PLIAGLIS
✉ Email this page to a colleague
All Clinical Trials for PLIAGLIS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00107835 ↗ | Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults | Completed | ZARS Pharma Inc. | Phase 3 | 2005-05-01 | The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in adults. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure. |
| NCT00110253 ↗ | Duration of Skin Numbing Effect Created by the S-Caine™ Peel | Completed | ZARS Pharma Inc. | Phase 3 | 2005-06-01 | S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a new skin numbing cream made of lidocaine and tetracaine. The purpose of this study is to evaluate and measure the length of time the S-Caine Peel numbs the skin, when applied for 30 and 60 minutes. |
| NCT00110747 ↗ | S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults | Completed | ZARS Pharma Inc. | Phase 3 | 2005-06-01 | Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe. For this reason, local anesthesia is commonly used to eliminate or minimize the pain. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate if S-Caine Peel is effective in providing topical local dermal anesthesia for non-ablative facial laser resurfacing in adults. |
| NCT00110760 ↗ | S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Skin Filler Injection in the Face | Completed | ZARS Pharma Inc. | Phase 3 | 2005-06-01 | Injection of dermal filler is used as an aesthetic treatment to fill in unwanted wrinkles and scars. There can be substantial pain associated with dermal filler injections. For this reason, local anesthesia is often used to eliminate or minimize the pain. This anesthesia can be administered by injection or through the use of topical creams and ointments. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate if S-Caine Peel is effective in providing topical local dermal anesthesia for dermal filler injections in adults. |
| NCT00110773 ↗ | S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Pulsed Dye Laser (PDL) Therapy in Adults | Completed | ZARS Pharma Inc. | Phase 3 | 2005-06-01 | Pulsed dye laser (PDL) on the face is painful. For this reason, local anesthesia is commonly used to eliminate or minimize the pain. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate the efficacy of S-Caine Peel for induction of local dermal anesthesia for PDL therapy in adults. |
| NCT00125255 ↗ | S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children | Completed | ZARS Pharma Inc. | Phase 3 | 2005-06-01 | The pain associated with medical procedures is often under-treated in children. Children often undergo painful procedures with little or no anesthetic, even when effective therapy is available. Reasons for not providing available therapy in children include concerns over adverse side effects as well as the length of time necessary to provide adequate anesthesia. Recent guidelines strongly advocate for the proactive treatment of pain in children, including the pain associated with medical procedures. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate whether S-Caine Peel is effective in providing topical local dermal anesthesia prior to a vascular access procedure in children 5 through 17 years of age. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PLIAGLIS
Condition Name
Clinical Trial Locations for PLIAGLIS
Trials by Country
Clinical Trial Progress for PLIAGLIS
Clinical Trial Phase
Clinical Trial Sponsors for PLIAGLIS
Sponsor Name
